Alto Neuroscience Faces Class Action Lawsuit Over IPO and Stock Sales.
PorAinvest
sábado, 16 de agosto de 2025, 10:31 am ET1 min de lectura
ANRO--
Key Details:
- Filing Date: August 15, 2025
- Court: United States District Court for the Northern District of California
- Plaintiffs: Investors who purchased or acquired Alto securities during the relevant time frame
- Claim: Defendants made false and misleading statements regarding ALTO-100's effectiveness in treating major depressive disorder (MDD), leading to overstated clinical, regulatory, and commercial prospects for the company.
Class Definition:
The class consists of all persons and entities that purchased or otherwise acquired:
- Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 2, 2024; and/or
- Alto securities between February 2, 2024, and October 22, 2024, both dates inclusive.
Next Steps:
Investors who believe they may be eligible to participate in the lawsuit have until September 19, 2025, to request that the Court appoint them as lead plaintiff. Participation in the lawsuit does not require that individuals serve as lead plaintiffs. There is no cost or obligation to participate.
Law Firms Involved:
- Levi & Korsinsky, LLP: Over 20 years of experience in securing hundreds of millions of dollars for aggrieved shareholders. [1]
- Pomerantz LLP: A premier firm in corporate, securities, and antitrust class litigation, with a history of recovering billions of dollars in damages awards. [2]
Contact Information:
- Levi & Korsinsky, LLP: Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
- Pomerantz LLP: Danielle Peyton at newaction@pomlaw.com or (646) 581-9980 ext. 7980.
References:
[1] https://www.marketscreener.com/news/alto-neuroscience-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsins-ce7c51dedf8cf625
[2] https://www.morningstar.com/news/pr-newswire/20250816dc48906/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-alto-neuroscience-inc-and-certain-officers-anro
A class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO) and certain officers, alleging securities law violations related to the company's initial public offering (IPO) and subsequent stock sales between February 2024 and October 2024. The lawsuit claims that defendants made false and misleading statements in IPO documents and during the Class Period. Investors who purchased or acquired Alto securities during this time may be eligible to participate in the lawsuit.
A class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO) and certain officers, alleging securities law violations related to the company's initial public offering (IPO) and subsequent stock sales between February 2024 and October 2024. The lawsuit claims that defendants made false and misleading statements in IPO documents and during the Class Period.Key Details:
- Filing Date: August 15, 2025
- Court: United States District Court for the Northern District of California
- Plaintiffs: Investors who purchased or acquired Alto securities during the relevant time frame
- Claim: Defendants made false and misleading statements regarding ALTO-100's effectiveness in treating major depressive disorder (MDD), leading to overstated clinical, regulatory, and commercial prospects for the company.
Class Definition:
The class consists of all persons and entities that purchased or otherwise acquired:
- Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 2, 2024; and/or
- Alto securities between February 2, 2024, and October 22, 2024, both dates inclusive.
Next Steps:
Investors who believe they may be eligible to participate in the lawsuit have until September 19, 2025, to request that the Court appoint them as lead plaintiff. Participation in the lawsuit does not require that individuals serve as lead plaintiffs. There is no cost or obligation to participate.
Law Firms Involved:
- Levi & Korsinsky, LLP: Over 20 years of experience in securing hundreds of millions of dollars for aggrieved shareholders. [1]
- Pomerantz LLP: A premier firm in corporate, securities, and antitrust class litigation, with a history of recovering billions of dollars in damages awards. [2]
Contact Information:
- Levi & Korsinsky, LLP: Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
- Pomerantz LLP: Danielle Peyton at newaction@pomlaw.com or (646) 581-9980 ext. 7980.
References:
[1] https://www.marketscreener.com/news/alto-neuroscience-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsins-ce7c51dedf8cf625
[2] https://www.morningstar.com/news/pr-newswire/20250816dc48906/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-alto-neuroscience-inc-and-certain-officers-anro
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios